Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Fish and Richardson
Queensland Health
QuintilesIMS
Argus Health
Chubb
Teva
Harvard Business School
McKesson

Generated: April 21, 2018

DrugPatentWatch Database Preview

NUMORPHAN Drug Profile

« Back to Dashboard

When do Numorphan patents expire, and what generic alternatives are available?

Numorphan is a drug marketed by Endo Pharms and is included in one NDA.

The generic ingredient in NUMORPHAN is oxymorphone hydrochloride. There are nine drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the oxymorphone hydrochloride profile page.
Drug patent expirations by year for NUMORPHAN
Medical Subject Heading (MeSH) Categories for NUMORPHAN
Synonyms for NUMORPHAN
(-)-Oxymorphone
(14S)-14-Hydroxydihydromorphinone
(1S,5R,13R,17S)-10,17-dihydroxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0;{1,13}.0;{5,17}.0;{7,18}]octadeca-7(18),8,10-trien-14-one
(1S,5R,13R,17S)-10,17-DIHYDROXY-4-METHYL-12-OXA-4-AZAPENTACYCLO[9.6.1.0(1),(1)(3).0?,(1)?.0?,(1)?]OCTADECA-7(18),8,10-TRIEN-14-ONE
(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one
(5alpha)-3,14-dihydroxy-17-methyl-4,5-epoxymorphinan-6-one
(5alpha)-4,5-Epoxy-3,14-dihydroxyl-17-methylmorphinan-6-one
10,17-dihydroxy-4-methyl-(13R,17S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one
10,17-dihydroxy-4-methyl-(13R,17S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one(oxymorphone)
10,17-dihydroxy-4-methyl-(13R,17S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one(xymorphone)
10,17-dihydroxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18)-trien-14-one
14-Hydroxydihydromorphinone
3,14-Dihydroxy-4,5-alpha-epoxy-17-methylmorphinan-6-one
357-07-3 (hydrochloride)
4,5-Epoxy-3,14-dihydroxy-N-methyl-6-oxomorphinan
4,5alpha-Epoxy-3,14-dihydroxy-17-methyl morphinan-6-one
7,8-Dihydro-14-hydroxymorphinone
76-41-5
9VXA968E0C
AKOS015962232
API0003722
BDBM50001707
BRN 0041588
C-18811
C08019
CC-33434
CHEBI:7865
CHEMBL963
CS-2852
D02NSF
D08323
DB01192
DEA No. 9652
Dihydro-14-hydroxymorphinone
Dihydrohydroxymorphinone
Dihydroxymorphinone
DTXSID5023409
EINECS 200-959-7
EN3202
FT-0080194
GTPL7094
HSDB 8060
HY-B0618
Morphinan-6-one, 3,14-dihydroxy-4,5-alpha-epoxy-17-methyl-
Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-methyl-, (5-alpha)- (9CI)
Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-methyl-, (5alpha)-
Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-methyl-, (5alpha)- (9CI)
Morphinan-6-one, 4,5alpha-epoxy-3,14-dihydroxy-17-methyl- (8CI)
Morphinan-6-one,5-epoxy-3,14-dihydroxy-17-methyl-, (5.alpha.)-
Morphinan-6-one,5.alpha.-epoxy-3,14-dihydroxy-17-methyl-
Morphinone, 7,8-dihydro-14-hydroxy- (6CI,7CI)
Morphinone, dihydro-14-hydroxy-
NIH10323
NSC 19045
NSC-19045
NSC19045
Numorphone
Opana
Ossimorfone
Ossimorfone [DCIT]
Oximorfona
Oximorfona [INN-Spanish]
Oximorphonum
Oxymorphine
oxymorphone
Oxymorphone (abuse-resistant, pain)
Oxymorphone (abuse-resistant, pain), Pain Therapeutics/ King Pharmaceuticals
Oxymorphone (abuse-resistant, pain), Pain Therapeutics/Pfizer
Oxymorphone (INN)
Oxymorphone [INN:BAN]
Oxymorphone 0.1 mg/ml in Methanol
Oxymorphone 1.0 mg/ml in Methanol
Oxymorphone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
Oxymorphonum
Oxymorphonum [INN-Latin]
PL005498
SCHEMBL3571
UNII-9VXA968E0C
UQCNKQCJZOAFTQ-ISWURRPUSA-N
ZINC3875483

US Patents and Regulatory Information for NUMORPHAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Pharms NUMORPHAN oxymorphone hydrochloride SUPPOSITORY;RECTAL 011738-004 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Argus Health
Cantor Fitzgerald
Cerilliant
McKinsey
McKesson
Moodys
Johnson and Johnson
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.